Filing summary: Frequency Therapeutics, Inc. — Q3 2021
Entity note: The request identifies Korro Bio, Inc., but the supplied Form 10-Q is for Frequency Therapeutics, Inc. (Nasdaq: FREQ). This summary reflects the filing provided, for the quarter ended September 30, 2021; it is not a Korro Bio filing.
Business context and reporting period
Frequency was a clinical-stage regenerative medicine company developing therapies intended to activate progenitor cells. Its lead candidate, FX-322, was being studied for sensorineural hearing loss (SNHL). The unaudited financial statements cover the three and nine months ended September 30, 2021, with comparisons to the corresponding 2020 periods. Unless stated otherwise, financial amounts below are in millions of dollars.
Financial and operating metrics
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | $0.0 | $11.2 | $14.1 | $27.0 |
| Research and development expense | $15.7 | $10.2 | $48.2 | $25.6 |
| General and administrative expense | $9.3 | $6.5 | $28.6 | $18.7 |
| Total operating expenses | $25.0 | $16.7 | $76.7 | $44.3 |
| Net loss | $25.2 | $5.3 | $63.2 | $16.3 |
| Basic and diluted loss per share | $0.73 | $0.16 | $1.84 | $0.51 |
The company had no product-sales revenue. Reported revenue came from recognizing the $80.0 million Astellas upfront payment over the period of related FX-322 Phase 2a research and development services; that performance obligation was completed in June 2021. No operating margin is presented because revenue was collaboration revenue rather than product sales and was zero in Q3 2021.
For the nine months, net cash used in operating activities was $58.2 million, versus $30.4 million in 2020. Investing activities used $51.5 million, largely reflecting purchases of marketable securities, net of redemptions; financing activities provided $1.2 million. Cash, cash equivalents and restricted cash totaled $113.8 million at September 30, 2021.
At quarter-end, cash and cash equivalents were $112.0 million, and short- and long-term marketable securities totaled $48.4 million. Management reported cash, cash equivalents and marketable securities of $160.5 million. Current assets were $149.9 million and current liabilities $10.5 million. Total liabilities were $55.1 million, including a $15.0 million term loan and lease liabilities of approximately $31.0 million. Stockholders’ equity was $147.1 million; accumulated deficit was $158.6 million.
Material changes versus the prior comparable periods
- Q3 revenue fell to zero from $11.2 million; nine-month revenue declined by $13.0 million as the Astellas upfront fee was progressively recognized and the related services concluded.
- Q3 net loss widened to $25.2 million from $5.3 million; nine-month net loss widened to $63.2 million from $16.3 million. Higher R&D and G&A spending drove the increase.
- Nine-month R&D expense rose $22.6 million, including higher FX-322 external development spending and platform, early-stage research and unallocated costs. The filing cites increased headcount, outsourced research, and facility costs following the move to Lexington.
- Nine-month G&A expense rose $9.9 million, primarily from employee-related costs, including stock-based compensation.
- Cash, cash equivalents and restricted cash decreased by $108.4 million during the first nine months of 2021. The company also shifted funds into marketable securities.
- The $15.0 million term loan, entered into in December 2020, carried a 4.75% rate at September 30, 2021; interest-only payments were scheduled through November 2022, followed by principal and interest payments through May 2024.
Outlook, commentary, risks and unusual items
- Management estimated existing cash, cash equivalents and short-term investments would fund operating expenses and capital needs into late 2023, while cautioning that this estimate depends on assumptions and funds could be used sooner. The company expected substantial ongoing losses and said additional financing would be required.
- FX-322 Phase 2a final results showed that four weekly injections did not improve hearing measures versus placebo. Management reported an unexpected increase in placebo-group word-recognition scores that complicated interpretation. The trial showed a favorable safety and tolerability profile.
- Management cited encouraging hearing responses in the Phase 1b FX-322-111 study, while noting that the age-related hearing loss study, FX-322-112, did not show a significant treatment effect versus placebo. Topline results from the fully enrolled severe-SNHL study, FX-322-113, were expected in Q4 2021.
- After quarter-end, the company commenced the FX-322-208 Phase 2b study in October 2021. In November 2021, it introduced FX-345 and FREQ-162; management anticipated filing an IND for FX-345 in Q2 2022. These are subsequent-period developments, not Q3 results.
- Key risks include clinical and regulatory uncertainty, dependence on FX-322, potential trial disruption from COVID-19, reliance on third-party manufacturers and research organizations, competition, and the need for additional capital. The company’s Astellas collaboration includes potential development and commercial milestones and royalties, none of which should be treated as assured future proceeds.
- Two securities class actions concerning statements about FX-322-202 and a separate Delaware stockholder lawsuit were pending. The company said it could not estimate possible losses and recorded no accruals for these matters as of September 30, 2021; it stated it was defending the claims.
- Management concluded disclosure controls and procedures were effective at the reasonable-assurance level as of September 30, 2021 and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the filing issuer: the provided document is Frequency Therapeutics, Inc., not Korro Bio, Inc.
- Review final and subsequent clinical data for FX-322, especially Phase 2b FX-322-208 and the severe-SNHL FX-322-113 study, including endpoints, statistical results, and safety.
- Assess the assumptions behind management’s late-2023 cash runway estimate, expected development spending, and potential financing needs.
- Review the term-loan repayment terms, security interest, and lease obligations, alongside the company’s cash and marketable-securities balances.
- Monitor the status and potential financial impact of the pending lawsuits, for which the company had not estimated a loss range.